Ketotifen 0.001g, 2p x 30 tablets — Made in Ukraine — Free Delivery

Antihistamines for systemic use.

Ketotifen belongs to the group of cycloheptothiophenones and has a pronounced antihistamine effect. It belongs to the group of non-bronchodilating anti-asthma preparations. The mechanism of its action is associated with inhibition of the release of histamine and other mediators of mastatsytam, with blocking of histamine H1 receptors and inhibition of the phosphodiesterase enzyme, as a result of which the level of cAMP in mast cells increases. Suppresses the effects of TAF (platelet-activating factor). When used alone, it does not stop attacks of bronchial asthma, but prevents their occurrence and leads to a reduction in their duration and intensity, while in some cases they completely disappear.

It is almost completely absorbed from the digestive tract. The maximum plasma level is reached in 2-4 hours. The equilibrium state is achieved after taking the minimum daily dose, which is 2 mg. Binds to blood plasma proteins by about 75%. The volume of distribution is 2.7 l / kg.

About 60% of the dose taken is metabolized in the liver in three ways (demethylation, N-oxidation, N-glucuroconjugation) to the following metabolites: ketotifen-N-glucuronide (pharmacologically inactive), norketotifen (with pharmacological activity similar to that of unchanged ketotifen), N-oxide ketotifen and

10-hydroxyketotifen (with unknown pharmacological activity).

It is excreted biphasically, with a short half-life of 3 to 5 hours and a longer period of 21 hours. About 1% is excreted unchanged in the urine within 48 hours, 60–70% - in the form of metabolites.

Preventive treatment of bronchial asthma, especially atopic asthma.

Symptomatic treatment of allergic conditions, including allergic rhinitis and conjunctivitis.

Hypersensitivity to ketotifen or to other components of the preparation.

Avoid the simultaneous use of ketotifen and oral antidiabetic agents (risk of developing reversible thrombocytopenia) until this phenomenon is sufficiently understood.

Active substance: ketotifen;

1 tablet contains ketotifen (in the form of ketotifen hydrofumarate) - 1 mg (0.001 g);

excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate, colloidal anhydrous silicon dioxide, talc.

With the simultaneous use of ketotifen and oral antidiabetic agents, there is a risk of reversible thrombocytopenia, therefore, this combination of preparations should be avoided.

With the simultaneous use of atropine, agents with atropine-like action and ketotifen, the risk of side effects, such as urinary retention, constipation, and dry mouth, increases.

Ketotifen can potentiate the effects of other preparations that depress the central nervous system (sedatives, hypnotics). The simultaneous use of ketotifen with other antihistamines can lead to the mutual potentiation of their effects. Ethanol enhances the depressive effect of ketotifen on the central nervous system.